FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average	burden
nours per response	e 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response		*	1 2 1	Iaanan Nan		ad Tiel		ruo din o	C	l. a l		5	Relation	shin of Rer	orting Perso	n(s) to Issu	er e	\equiv
Name and Address of Reporting Person Schorno Dean L					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 05/22/2019								X Officer (give title below) Other (specify below) EVP & Chief Financial Officer						
(Street)				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person							
		NCISCO,													d by More than	One Reporting	1 CISOII		
(City	")	(State)	(Zip)			Ta	ble I - 1	Non-D	erivati	ve S	Securiti	ies Ac	quir	ed, Dispo	osed of, or l	Beneficially	Owned		
1.Title of Security 2. Transaction (Instr. 3) Date (Month/Day/Ye					, if	(Instr. 8)		1 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)			Ownership of	of Indi	Nature f Indirect eneficial		
				(Mont	th/Day/Ye	ear)	Code	V	Amo	unt	(A) or (D)	Prio	ce	(Instr. 3 and 4) Direct (D) or Indirect (I) (Instr. 4)			Owner (Instr.		
Common	Stock		05/22/2019				P		46,7	26	A	\$ 2.13	31	46,726	726		D		
Common	Stock		05/22/2019				P		3,27	4	A	\$ 2.12	292	2 50,000			D		
Reminder:	Report on a s	separate line f	for each class of secu	ırities b	peneficiall	y ow	vned di	ectly o	or indire	ectly	y								
								со	ntaine	d ir	n this f	form	are i	not requ		ormation spond unleading troining troining transfer in the contract of the co	ss	C 1474 (9	9-02)
			Table II -		ative Secu		_		-					y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ion Date (Month/Day/	(Month/Day/Year) any	``		ion 1 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	5.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Tit Amor Unde Secur		rlying rities . 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transactions (Instr. 4)	Ownersh Form of Derivati Security Direct (I or Indire	ship of I Ber Ow (Instance of Instance of I Ber Ow (Instance of Instance of I Ber Ow (Instance of Instance of I Ber Ow (Instance of	. Natur Indirect eneficia wnersh astr. 4)	
					Code	V	(A) (ate cercisat		Expirat Date	tion T		Amount or Number of Shares					

Reporting Owners

		Relationships						
Reporting Owner Name /	Address	Director	10% Owner	Officer	Other			
Schorno Dean L RIGEL PHARMACEUTIC 1180 VETERANS BLVD. SOUTH SAN FRANCISCO	,			EVP &Chief Financial Officer				

Signatures

/s/Dolly Vance (Attorney-in-Fact)	05/23/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.